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While measures such as closing schools and social
distancing may slow the effects of pandemic influenza, only
vaccines and antiviral drugs are clearly efficacious in pre-
venting infection or treating illness. Unless the pandemic
strain closely resembles one already recognized, vaccine
will not be available early. However, studies can be con-
ducted beforehand to address questions concerning vac-
cine dose, frequency of inoculation, and need for
adjuvants. In contrast, antiviral drugs, particularly the neu-
raminidase inhibitors, will be effective for treatment and
available if stockpiling takes place. Special questions need
to be answered if a highly lethal virus, such as influenza A
(H5N1), produces the pandemic. Both vaccines and antivi-
ral drugs will be required for a coordinated strategy.
P
revention of influenza, particularly during a pandemic,
may be attempted by many measures, such as closing
schools, using facemasks, and keeping infected persons
away from those susceptible, now termed social distanc-
ing. However, none of these measures are of clear value in
preventing infection, even if they could be accomplished.
A principal reason little effort has been made to determine
their usefulness in the interpandemic period is the usual
availability of vaccine, which is of known value in preven-
tion. Thus, few studies have been undertaken. Similarly,
symptomatic therapy is possible and perhaps appropriate
in treating milder illnesses. Antimicrobial drugs are neces-
sary when bacterial complications occur. However, antivi-
ral drugs are specific and can not only prevent infection
but also treat illness (1).
Apandemic virus will likely spread so rapidly from the
source that vaccine availability may be delayed for months
after major outbreaks begin. In addition, much of the pop-
ulation will be totally susceptible. We will likely not be
able to prepare stockpiles of virus concentrates well
matched with the pandemic strain for vaccine production
before the strain has actually shown itself. In contrast,
antiviral drugs, particularly the neuraminidase inhibitors
(NAIs), will be effective against any pandemic virus, and
stockpiling is possible (1). However, supplies will likely
be limited, even with a relatively large stockpile, and may
well be exhausted without careful planning before vaccine
is available.
Vaccines: Needs and Priorities 
in the Prepandemic Phase
Key to the ability to have vaccines ready is early detec-
tion of the pandemic virus. Improved surveillance net-
works are vital for this purpose. While the specific variant
that emerges will probably be different antigenically from
any recognized, much can be learned by studying the
known variants of likely subtypes. An example of what
needs to be done before the pandemic is the concerted
evaluation in 1976 of a virus variant thought to have pan-
demic potential (2). The swine influenza virus, detected in
humans in that year, was viewed as a pandemic threat.
Because the pandemic never occurred, researchers had
time to complete a large range of pediatric and adult stud-
ies. We learned that those who had no previous experience
with that subtype needed to be vaccinated twice with a
split preparation. The whole-virus vaccine then commonly
used could not be given to those persons without frequent
systemic reactions, but the whole-virus vaccine was more
immunogenic and might be acceptable if rapid response
was desired. In persons previously exposed to the influen-
za virus subtype, the whole-virus vaccine was much less
reactogenic and appeared more immunogenic than the split
product (3,4). These observations still have relevance in
the current situation.
Similar studies need to be carried out now on all sub-
types of pandemic potential. However, we cannot do so
without choosing priorities, given restrictions of time and
resources. Choices must be made on the basis of historic
and current observations. At one time, a closed, fixed cycle
of type A subtypes was thought to exist, with one follow-
ing the other, each producing a pandemic (5). This theory
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viruses and was based as a classification system derived
from their epidemiologic characteristics. As shown in the
Table, the concern that swine influenza would appear in
1976 was supported by seroarcheology, evidence in serum
samples collected before, for example, 1968 that an A(H2)
and A (H3) virus had previously circulated (6). Few cur-
rently believe this theory in its entirety, since it would
require that a subtype remain undetected in a host, perhaps
in humans, for a long period of time. However, the deter-
mination, using molecular techniques unavailable until
well after the pandemics had occurred, that the A (H2N2)
and A (H3N2) viruses were reassortants between previous
human and avian strains suggested a different origin for
these viruses (7,8). The avian predecessors of these 2 new
viruses were not highly pathogenic, and the resultant pan-
demics showed a typical U-shaped death rate, highest in
the very young and old. The 1918 virus had a different der-
ivation and was apparently not a reassortant but a mutant.
It also had an avian origin, but the progenitor virus has not
yet been identified, so its pathogenicity in birds is
unknown (9). However, its epidemiologic signature in
humans was high case fatality in young adults (10).
The question, then, based on this evidence, is which
viruses should be studied to prepare a vaccine to control
the next pandemic? Will type A (H2N2) return, in keeping
with the recycling theory? Much of the population will
now be susceptible. Type A (H9N2), a less pathogenic
avian virus, has transmitted occasionally to humans, with
little or no further transmission, but has not produced dis-
ease with high case fatality (11). The highly pathogenic
type A (H5N1) virus is at the top of the list of potential
pandemic threats. This virus, if it becomes adapted for
human transmission without a reduction in virulence,
could result in a pandemic far worse than 1918, also
involving healthy, younger persons (12,13). Other viruses,
such as the A(H7) highly pathogenic avian strains, includ-
ing A (H7N7), which infected humans in the Netherlands,
and A (H7N3), which spread extensively in western
Canada, can also be considered candidates but are not as
high on the list since fewer transmissions to humans and
less clinical disease have been seen (14,15). 
Prepandemic Vaccine Evaluation
Scientific questions that have been raised concerning
the various priority potential pandemic viruses are differ-
ent, depending on the specific subtypes. The goal in all
cases is production of an immune response with the least
amount of antigen, so that more doses can be available.
Perhaps the simplest situation is that of A (H2N2), a
known quantity, because of its presence from 1957 to
1968, in terms of immune response, population likely to be
infected, and expected disease characteristics. Also, that
virus presents the fewest issues about vaccine production,
for the same reasons. However, the basic question relates
to producing the best immune response with the least
amount of antigen and avoiding if possible the need for a
second injection, which would use additional antigen and
delay production of protective immunity. One approach,
already studied, is to leave the harvested virus particles
intact, the modern equivalent of the whole-virus vaccines
evaluated in 1976 (16). In persons without prior infection
with this virus, 1 injection of as little as 3.8 µg with alum,
a widely used adjuvant, produced some antibody response,
as determined by the hemagglutination-inhibition (HAI)
test, traditionally used to assess protection afforded by
inactivated vaccines. A second injection produced high
titers. Positive features of this approach are that vaccine
could be produced more quickly, and antigen would be
spared. A possible negative feature would be reactogenici-
ty in children. However, we do not know whether, with
modern purification methods, these vaccines would have
the reactogenicity of those produced in 1976. Less work
has been done with avian influenza, A (H9N2), but similar
approaches might be used with these nonhighly pathogen-
ic avian viruses (16,17).
The highly pathogenic A (H5N1) virus presents many
more problems in vaccine development and evaluation.
The first one, already solved, involves removal of the
molecular motif of high pathogenicity, the multibasic
cleavage site, from the hemagglutinin. The virus is then
reassembled by using reverse genetics, but on a back-
ground of the high-growth type A virus, PR8 (18).
Producing vaccine by using this engineered virus can then
proceed without high-level containment. However, we
know from previous work with a less pathogenic influen-
za, A (H5N3) that antibody response to this avian subtype
is not good and that adjuvants and multiple doses are
required (19,20). The A(H5N3) vaccine was given to only
small numbers of healthy adults. Response did not occur in
persons given <30 µg of antigen alone but did in persons
given the antigen with the MF-59 adjuvant. However, after
16 months, essentially no antibody was seen even in those
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with the same preparation, persons previously given the
vaccine with adjuvant had an anamnestic response, while
persons given the unadjuvanted vaccine again had a poor
response. Measuring and evaluating the meaning of the
antibody response to some avian viruses is also an issue.
Even infection with the A (H5N1) virus does not produce
a good HAI antibody response; the antibody needs to be
detected with a neutralization test (21). Similarly, neutral-
ization testing is necessary to detect response to vaccine;
however, a specific level of HAI antibody has been associ-
ated with protection, but no similar correlate of neutraliza-
tion antibody has yet been developed (5).
Further evaluation of dosage and need for booster injec-
tion of these vaccines is in process. An international agen-
da is needed so that the diverse issues will be
systematically investigated. Several high-priority vaccines
need to be evaluated at various frequencies of administra-
tion and dose levels, with and without adjuvants. No single
country can do it adequately (10). The work has started,
especially with the A(H5N1) vaccine produced by reverse
genetics, but the research has a long way to go.
Antiviral Drugs: What Can be Done 
Before the Pandemic
With antiviral drugs, the scientific questions that need
to be answered before the pandemic are not as daunting
(13). Originally, both classes of antiviral drugs were
believed to be effective against a pandemic virus.
Adamantane action is limited to type Aviruses, but all pan-
demic viruses are type A (15). The neuraminidases of
many different type A viruses have been evaluated with
respect to NAIs, and all have been found susceptible (1).
As a result, given advance planning so that supplies are
available, antiviral drugs can be used early in a pandemic
and do not require specific production and formulation.
Because they are much less costly than NAIs, adamantanes
were part of the overall antiviral strategy (20). Having 2
classes of drug increased the amount of antiviral drugs
available to stockpile since production limitations are an
issue with the NAIs.
Considerable evidence indicates that both classes of
drugs work well in prophylaxis against susceptible season-
al influenza viruses and that prophylaxis does not increase
resistance. In fact, amantadine prophylaxis has been tested
in a pandemic situation, and while efficacy may be reduced
in persons with no previous exposure, which seems to
increase protection, it is still 70%–80% (22). Although no
direct comparisons have been carried out with the adaman-
tanes, NAIs appear at least as efficacious. The 2 NAIs,
zanamivir and oseltamivir, gave similar results when given
daily for 4 or 6 weeks (23,24). They may be more effica-
cious in preventing febrile illnesses, although asympto-
matic infection often still occurs. This characteristic is
actually desirable, since it provides protection against the
next wave of the pandemic virus. However, in some cases,
infection is prevented completely, so vaccine should be
used when available.
In treatment, adamantanes and NAIs diverge in their
efficacy. No reliable data on use in pandemics exists, and
no head-to-head studies have been carried out. Studies of
treatment with amantadine and rimantadine did not allow
firm estimates of how much they shortened duration of ill-
ness but were sufficient to conclude that they produced
more rapid resolution than symptomatic therapy, such as
aspirin (25). No data suggest that they prevented compli-
cations in any population; indeed, recent experimental
studies suggest that they do not (26). However, the main
reason they have never been considered for therapy in a
pandemic is that antiviral resistance occurs in >30% of
those given the drug for treatment and that resistant virus-
es are fully pathogenic and transmissible (27). While
resistance occurs when oseltamivir is used in treatment, it
is far less frequent than with the adamantanes, and the
mutant viruses may be less infectious and transmissible
than wild type (28–30). This conclusion cannot be viewed
as absolute; with high-volume use, which has occurred
thus far only in Japan, resistant viruses could begin to cir-
culate. Emergence of resistance has apparently occurred
with adamantanes, and the more recent type A (H5N1)
virus, as well as some currently circulating seasonal virus-
es, are not susceptible to this drug class.
Another advantage of NAIs in therapy is their ability to
prevent certain complications (31,32). Some evidence also
shows increased efficacy in illnesses that are identified as
more severe at onset (33). We cannot predict how this effi-
cacy would translate into treatment success in a pandemic,
but it encourages using them to treat persons who are rec-
ognized early to be more symptomatic.
With ordinary influenza viruses of pandemic potential,
such as type A(H2N2) and A(H9N2), treatment success in
the interpandemic period would be more likely relevant to
the pandemic. Such may not be the case with the type A
(H5N1) virus. The virus has evolved since the 1997 Hong
Kong outbreak, and some evidence of a systemic infection
involving the brain and gastrointestinal tract exists (12,34).
This infection has also been demonstrated in laboratory
animals such as ferrets (35) and means that the drug may
need to reach adequate concentration in these sites, remote
from the respiratory tract. Zanamivir is not orally bioavail-
able and is thus not likely to be useful in treating influen-
za A (H5N1) infection, although it might play a role in
prophylaxis. Oseltamivir, in contrast, is absorbed and
metabolized. While human studies of oseltamivir in treat-
ment would be critical now, such studies have been diffi-
cult to carry out, since the disease has been occurring in
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have yet to determine whether the mixed results that have
been described with this drug in the limited case reports
are due to late treatment or other factors, such as need for
higher doses (13,35). Aplanned clinical trials network may
solve this problem. In the meantime, animal studies are
urgently needed to evaluate dosage and duration of thera-
py, particularly against the Vietnam strain of the A(H5N1)
virus. These studies would help guide treatment of human
cases until more data are available. Mouse studies have
already indicated that, while oseltamivir is effective, it is
not as effective when given for 5 days as it was against the
1997 Hong Kong variant of A(H5N1) influenza (36). This
finding indicates that treatment for 10 days might be nec-
essary, since in the mouse studies, replication resumed
after therapy was stopped. The dose may also need to be
increased. Studies in ferrets and nonhuman primates would
have more relevance to the situation in humans than stud-
ies in mice.
Vaccine Activities in the Pandemic
Countries will need to have pandemic plans in place to
establish priorities for vaccine use. However, to help refine
these decisions once the pandemic begins, epidemiologic-
and vaccine-related issues will have to be addressed. The
pandemic must be characterized not only in terms of the
groups infected but also, more importantly, case fatality in
each group. Vaccine supply will be increasing over time,
so the question is which groups should get it earlier.
Current pandemic planning usually directs vaccine to the
groups who traditionally have had the highest death rates,
mainly the old and the very young, but this might have to
change. If the 1918 pattern repeated itself, or for example,
if the A (H5N1) virus produces the pandemic and does not
change in virulence or its tendency to infect the young,
vaccination priorities would have to be changed radically.
Once the pandemic virus is available, a rapid evaluation
will be needed to address questions of dosage, need for
adjuvants, and booster vaccination. However, this evalua-
tion will need to be done quickly, especially for regions of
the world close to the pandemic origin, so as much work as
possible should be done before the pandemic. First,
though, a virus for vaccine production will need to be cre-
ated from the pandemic strain, with appropriate manipula-
tion to make it high yielding. In the process, the molecular
and antigenic differences between this virus and those of
the same subtype already available will need to be defined.
With luck, the pandemic virus may be similar enough to
one already studied so that any available concentrates can
be used. However, similarity is unlikely because of the
antigenic variation of influenza strains within a subtype.
Rather than stockpiling, another strategy needs to be con-
sidered for vaccines containing a virus such as A (H5N1)
for which vaccine development has already begun. That
virus can be included in vaccines in use before the pan-
demic. Although influenza A(H5N1) virus has been evolv-
ing, even a poorly matched vaccine might provide some
protection, especially against a variant with such high
lethality (37). Also, if 2 injections of a specific vaccine are
necessary, an older vaccine could prime, so that only 1
injection of the new vaccine would be needed. An A
(H5N1) vaccine might initially be directed for use in areas
such as Southeast Asia, which are experiencing continued
avian transmission and occasional spread to humans.
A live, attenuated vaccine would more likely produce
antibodies after 1 injection and would have a number of
other theoretical advantages over inactivated vaccine in a
pandemic. Unfortunately, such a vaccine will not general-
ly be considered for 2 reasons. First, production requires
specific pathogen–free eggs and these will be in shorter
supply than ordinary eggs. This could change if cell culture
could be used. However, the bigger problem involves eval-
uation before and use early in the pandemic. Since this
vaccine virus could reassort, it might introduce the pan-
demic virus into the population if used too early. The ques-
tion also arises whether attenuation would be successful
with a new and potentially more virulent wild type, a result
which could be evaluated in advance in animals (38).
Antiviral Drugs in the Pandemic
While supplies of vaccines will increase as the pandem-
ic evolves, antiviral drug supplies will decrease as stock-
piles are depleted. The starting level will depend on the
amount of stockpiling, based more on economic and poli-
cy consideration than science. As with vaccines, planning
decisions will be in place to prioritize use during the initial
period, which may need to be modified based on epidemi-
ologic characteristics of the outbreak and clinical charac-
teristics of the cases. The key virologic issue will be
whether the pandemic strain is susceptible to the antiviral
drugs. Most recent planning, since it is focused on the
threat of the A (H5N1) virus, has assumed that adaman-
tanes would not be useful. This assumption means that if
the disease is systemic and case fatality is high, among the
NAIs only oseltamivir would be useful, since it is absorbed
(39). Given the limited quantities likely to be available, at
least in the near future, the drug will have to be restricted
to treat those most likely to die or have severe conse-
quences. Careful observation of treatment results will help
to determine if the dose and duration of therapy is appro-
priate. Seasonal prophylaxis uses larger quantities of drug,
but possibly limited postexposure use could be feasible.
Zanamivir, if available, might find its role in prevention.
Infection is likely through the respiratory tract, and given
past evidence, the drug could make a major contribution in
prophylaxis before vaccine is available. Throughout,
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ance, which might emerge as a problem with extensive use
of the drugs. A long-term goal should be to develop new
antiviral agents against influenza. The global reliance on
basically 1 drug from 1 source cannot be allowed to con-
tinue. Other NAIs are available for clinical evaluation, and
drugs targeting other phases of influenza viral replication
would be especially useful.
Given the threat of a virulent virus such as A (H5N1)
and the suggestion that adaptation to transmissibility may
occur gradually, the concept has emerged that antiviral
drugs may be used to interrupt early, local transmission.
The aim would be to prevent spread out of the region of
origin, in other words, extinguishing the epidemic at its
source (40). Transmission models suggest that this strate-
gy will work as long as the Ro or basic reproductive num-
ber is not high (41). Thus, this goal seems worthy of
consideration on more than a theoretical basis. Models also
suggest that the approach might be more likely to succeed
with partial immunity in the population (42). This immu-
nity could be produced by prior vaccination with a current
A(H5N1) vaccine. Practical issues may be of greatest con-
cern, especially the ability to put antiviral prophylaxis in
place rapidly in rings around cases. Supplies of oseltamivir
are also an issue. Will those countries with stockpiles be
willing to share with other countries on the possibility, not
certainty, that a pandemic could be avoided?
Conclusion
Major challenges are presented in controlling a pan-
demic with vaccine and antiviral drugs, particularly one
caused by an A(H5N1) virus similar to those currently cir-
culating. Some are specific to the particular intervention,
but others are more generic. Long-term needs exist, such
as developing innovative technologies for vaccine preven-
tion and designing antiviral drugs to affect different tar-
gets. However, immediate attention for vaccines must be
directed to a coordinated international approach to vaccine
evaluation, paying attention to ways in which the least
amount of virus can immunize the largest number of per-
sons. Use of a possibly unmatched A (H5N1) vaccine for
priming should be considered, especially in Southeast
Asia, or other areas with the most pressing need. In those
regions, antiviral strategies need to be evaluated; drug
studies in animal models will be necessary, given the spo-
radic nature of the disease in humans. Overall, developing
countries will have limited access to vaccines and antiviral
drugs, and their needs must not be forgotten. With margin-
al healthcare infrastructures, they will suffer the most,
whatever the severity of the pandemic.
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